Recombinant Human RETN Protein，His

RETN, or resistin, is a protein primarily produced by adipose tissue and is known for its role in insulin resistance and obesity-related pathologies. Research on RETN has accelerated in recent years due to its implications in metabolic disorders, including type 2 diabetes and cardiovascular diseases. It is classified as an adipokine, a type of cytokine secreted by adipose tissue that mediates various physiological functions. Elevated levels of RETN have been associated with inflammation and carbohydrate metabolism dysregulation, positioning it as a potential biomarker for assessing metabolic health. Studies have demonstrated that RETN can affect insulin signaling pathways, further complicating the metabolic profiles of individuals with obesity. Furthermore, RETN's involvement in inflammatory processes suggests that it may serve as a link between obesity and the development of chronic inflammatory diseases. Investigating RETN’s structural and functional properties through recombinant protein technology has provided insights into its biological mechanisms and interactions with other signaling pathways. This enhances our understanding of its role in metabolism and opens avenues for therapeutic interventions targeting RETN or its signaling pathways to combat obesity and its associated complications. Given the rising global prevalence of obesity and metabolic syndrome, continued research on RETN as a pivotal factor in these conditions is crucial for developing effective treatments and preventive strategies.